Literature DB >> 9123027

Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy.

K Zucker1, A Rosen, A Tsaroucha, L de Faria, D Roth, G Ciancio, V Esquenazi, G Burke, A Tzakis, J Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9123027     DOI： 10.1016/s0041-1345(96)00292-8

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  10 in total

1.  A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients.

Authors:  R Shapiro; M L Jordan; V P Scantlebury; C Vivas; J W Marsh; J McCauley; J Johnston; P Randhawa; W Irish; H A Gritsch; R Naraghi; T R Hakala; J J Fung; T E Starzl
Journal:  Transplantation       Date:  1999-02-15       Impact factor: 4.939

2.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 3.  Cytomegalovirus infection and abdominal pain with mycophenolate mofetil: is there a link?

Authors:  H Gallagher; P A Andrews
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.

Authors:  Serge Cremers; Rik Schoemaker; Eduard Scholten; Jan den Hartigh; Jacqueline König-Quartel; Eric van Kan; Leendert Paul; Johan de Fijter
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

Review 5.  Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

Authors:  C M Spencer; K L Goa; J C Gillis
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

6.  Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.

Authors:  L'aurelle A Johnson; William S Oetting; Saonli Basu; Susie Prausa; Arthur Matas; Pamala A Jacobson
Journal:  Eur J Clin Pharmacol       Date:  2008-06-21       Impact factor: 2.953

7.  Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events.

Authors:  Yuen Yi Hon; Christine E Chamberlain; David E Kleiner; Michael S Ring; Douglas A Hale; Allan D Kirk; Roslyn B Mannon
Journal:  Clin Transplant       Date:  2010 Jul-Aug       Impact factor: 2.863

8.  Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation.

Authors:  P Jacobson; S F El-Massah; J Rogosheske; A Kerr; J Long-Boyle; T DeFor; C Jennissen; C Brunstein; J Wagner; M Tomblyn; D Weisdorf
Journal:  Bone Marrow Transplant       Date:  2009-01-19       Impact factor: 5.483

9.  Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients.

Authors:  P Dalal; G Shah; D Chhabra; Lorenzo Gallon
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-08-04

10.  Clinical Outcomes Using Mycophenolate and Tacrolimus for Graft-versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplant: A Single Institution Experience.

Authors:  Hamza Hashmi; Shruti Bhandari; Jugraj Dhanoa; Xiaoyong Wu; Shesh Rai; Lindsay Figg; Timothy Baize; Maxwell Krem; Mohamed Hegazi; Robert Emmons
Journal:  Cureus       Date:  2020-02-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.